{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:07:50Z","timestamp":1783044470126,"version":"3.54.6"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1007\/s00415-005-1104-5","type":"journal-article","created":{"date-parts":[[2005,6,15]],"date-time":"2005-06-15T20:55:54Z","timestamp":1118868954000},"page":"i14-i18","source":"Crossref","is-referenced-by-count":25,"title":["IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status"],"prefix":"10.1007","volume":"252","author":[{"given":"Isabel","family":"Illa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"1104_CR1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<551::AID-MUS14>3.0.CO;2-O","volume":"23","author":"Achiron","year":"2000","unstructured":"Achiron A, Barak Y, Miron S, Sarova-Pinhas I (2000) Immunoglobulin treatment in refractory Myasthenia gravis. Muscle Nerve 23:551\u2013555","journal-title":"Muscle Nerve"},{"key":"1104_CR2","first-page":"2498","volume":"27","author":"Al-Mayouf","year":"2000","unstructured":"Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM (2000) Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27:2498\u20132503","journal-title":"J Rheumatol"},{"key":"1104_CR3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00000441-198805000-00005","volume":"295","author":"Arsura","year":"1988","unstructured":"Arsura EL, Bick A, Brunner NG, Grob D (1988) Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci 295:438\u2013443","journal-title":"Am J Med Sci"},{"key":"1104_CR4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","volume":"47","author":"Bain","year":"1996","unstructured":"Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, Vincent A, Lang B (1996) Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 47:678\u2013683","journal-title":"Neurology"},{"key":"1104_CR5","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1212\/WNL.42.7.1422","volume":"42","author":"Bird","year":"1992","unstructured":"Bird SJ (1992) Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology 42:1422\u20131423","journal-title":"Neurology"},{"key":"1104_CR6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0002-9343(91)90009-M","volume":"91","author":"Cherin","year":"1991","unstructured":"Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, Ziza JM, Godeau P (1991) Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 91:162\u2013168","journal-title":"Am J Med"},{"key":"1104_CR7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","volume":"46","author":"Cherin","year":"2002","unstructured":"Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, Maisonobe T, Eymard B, Herson S (2002) Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 46:467\u2013474","journal-title":"Arthritis Rheum"},{"key":"1104_CR8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0404.1991.tb04912.x","volume":"84","author":"Cosi","year":"1991","unstructured":"Cosi V, Lombardi M, Piccolo G, Erbetta A (1991) Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand 84:81\u201384","journal-title":"Acta Neurol Scand"},{"key":"1104_CR9","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"Dalakas","year":"1991","unstructured":"Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325:1487\u20131498","journal-title":"N Engl J Med"},{"key":"1104_CR10","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1212\/WNL.51.6_Suppl_5.S37","volume":"51","author":"Dalakas","year":"1998","unstructured":"Dalakas MC (1998) Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 51:S37\u2013S45","journal-title":"Neurology"},{"key":"1104_CR11","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B","volume":"22","author":"Dalakas","year":"1999","unstructured":"Dalakas MC (1999) Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 22:1479\u20131497","journal-title":"Muscle Nerve"},{"key":"1104_CR12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-2003-41136","volume":"23","author":"Dalakas","year":"2003","unstructured":"Dalakas MC (2003) Therapeutic approaches in patients with inflammatory myopathies. Semin Neurol 23:199\u2013206","journal-title":"Semin Neurol"},{"key":"1104_CR13","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.revmed.2004.04.007","volume":"25","author":"Dalakas","year":"2004","unstructured":"Dalakas MC (2004) The molecular pathophysiology in inflammatory myopathies. Rev Med Interne 25(Suppl 1):S14\u2013S16","journal-title":"Rev Med Interne"},{"key":"1104_CR14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971\u2013982","journal-title":"Lancet"},{"key":"1104_CR15","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993\u20132000","journal-title":"N Engl J Med"},{"key":"1104_CR16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","volume":"56","author":"Dalakas","year":"2001","unstructured":"Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E (2001) A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56:323\u2013327","journal-title":"Neurology"},{"key":"1104_CR17","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"Dalakas","year":"1997","unstructured":"Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K (1997) Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48:712\u2013716","journal-title":"Neurology"},{"key":"1104_CR18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/ard.61.1.37","volume":"61","author":"Danieli","year":"2002","unstructured":"Danieli MG, Malcangi G, Palmieri C, Logullo F, Salvi A, Piani M, Danieli G (2002) Cyclosporin A and intravenous immunoglobulin treatment in polymyositis\/dermatomyositis. Ann Rheum Dis 61:37\u201341","journal-title":"Ann Rheum Dis"},{"key":"1104_CR19","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","volume":"330","author":"Drachman","year":"1994","unstructured":"Drachman DB (1994) Myasthenia gravis. N Engl J Med 330:1797\u20131810","journal-title":"N Engl J Med"},{"key":"1104_CR20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","volume":"53","author":"Drachman","year":"2003","unstructured":"Drachman DB, Jones RJ, Brodsky RA (2003) Treatment of refractory myasthenia: \u201crebooting\u201d with high-dose cyclophosphamide. Ann Neurol 53:29\u201334","journal-title":"Ann Neurol"},{"key":"1104_CR21","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(84)92294-3","volume":"1","author":"Fateh-Moghadam","year":"1984","unstructured":"Fateh-Moghadam A, Wick M, Besinger U, Geursen RG (1984) High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1:848\u2013849","journal-title":"Lancet"},{"key":"1104_CR22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 41:789\u2013796","journal-title":"Ann Neurol"},{"key":"1104_CR23","first-page":"CD002277","volume":"Rev","author":"Gajdos","year":"2003","unstructured":"Gajdos P, Chevret S, Toyka K (2003) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev:CD002277","journal-title":"Cochrane Database Syst"},{"key":"1104_CR24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","volume":"55","author":"Gronseth","year":"2000","unstructured":"Gronseth GS, Barohn RJ (2000) Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55:7\u201315","journal-title":"Neurology"},{"key":"1104_CR25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365\u2013368","journal-title":"Nat Med"},{"key":"1104_CR26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-2004-829585","volume":"24","author":"Hughes","year":"2004","unstructured":"Hughes BW, Moro De Casillas ML, Kaminski HJ (2004) Pathophysiology of myasthenia gravis. Semin Neurol 24:21\u201330","journal-title":"Semin Neurol"},{"key":"1104_CR27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(81)90474-8","volume":"2","author":"Lang","year":"1981","unstructured":"Lang B, Newsom-Davis J, Wray D, Vincent A, Murray N (1981) Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 2:224\u2013226","journal-title":"Lancet"},{"key":"1104_CR28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-2004-830900","volume":"24","author":"Mareska","year":"2004","unstructured":"Mareska M, Gutmann L (2004) Lambert-Eaton myasthenic syndrome. Semin Neurol 24:149\u2013153","journal-title":"Semin Neurol"},{"key":"1104_CR29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jnnp.65.1.107","volume":"65","author":"Mastaglia","year":"1998","unstructured":"Mastaglia FL, Phillips BA, Zilko PJ (1998) Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 65:107\u2013110","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1104_CR30","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","volume":"321","author":"McEvoy","year":"1989","unstructured":"McEvoy KM, Windebank AJ, Daube JR, Low PA (1989) 3.4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 321:1567\u20131571","journal-title":"N Engl J Med"},{"key":"1104_CR31","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","volume":"61","author":"Meriggioli","year":"2003","unstructured":"Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, Sanders DB (2003) Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 61:1438\u20131440","journal-title":"Neurology"},{"key":"1104_CR32","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/(SICI)1097-4598(199706)20:6<674::AID-MUS3>3.0.CO;2-5","volume":"20","author":"Muchnik","year":"1997","unstructured":"Muchnik S, Losavio AS, Vidal A, Cura L, Mazia C (1997) Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve 20:674\u2013678","journal-title":"Muscle Nerve"},{"key":"1104_CR33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0035-3787(04)70888-7","volume":"160","author":"Newsom-Davis","year":"2004","unstructured":"Newsom-Davis J (2004) Lambert-Eaton myasthenic syndrome. Rev Neurol (Paris) 160:177\u2013180","journal-title":"Rev Neurol"},{"key":"1104_CR34","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50:1778\u20131783","journal-title":"Neurology"},{"key":"1104_CR35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.33588\/rn.3305.2001132","volume":"33","author":"Perez Nellar","year":"2001","unstructured":"Perez Nellar J, Dominguez AM, Llorens-Figueroa JA, Ferra-Betancourt A, Pardo A, Quiala M, Gali Z (2001) A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia. Rev Neurol 33:413\u2013416","journal-title":"Rev Neurol"},{"key":"1104_CR36","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.52.3.629","volume":"52","author":"Qureshi","year":"1999","unstructured":"Qureshi AI, Choudhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia AM, Ulatowski JA, Krendel DA, Leshner RT (1999) Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 52:629\u2013632","journal-title":"Neurology"},{"key":"1104_CR37","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","volume":"61","author":"Richman","year":"2003","unstructured":"Richman DP, Agius MA (2003) Treatment of autoimmune myasthenia gravis. Neurology 61:1652\u20131661","journal-title":"Neurology"},{"key":"1104_CR38","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","volume":"25","author":"Ronager","year":"2001","unstructured":"Ronager J, Ravnborg M, Hermansen I, Vorstrup S (2001) Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 25:967\u2013973","journal-title":"Artif Organs"},{"key":"1104_CR39","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","volume":"54","author":"Sanders","year":"2000","unstructured":"Sanders DB, Massey JM, Sanders LL, Edwards LJ (2000) A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 54:603\u2013607","journal-title":"Neurology"},{"key":"1104_CR40","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/mus.880170919","volume":"17","author":"Takano","year":"1994","unstructured":"Takano H, Tanaka M, Koike R, Nagai H, Arakawa M, Tsuji S (1994) Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody. Muscle Nerve 17:1073\u20131075","journal-title":"Muscle Nerve"},{"key":"1104_CR41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","volume":"2","author":"Vincent","year":"2003","unstructured":"Vincent A, Bowen J, Newsom-Davis J, McConville J (2003) Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2:99\u2013106","journal-title":"Lancet Neurol"},{"key":"1104_CR42","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1196\/annals.1254.036","volume":"998","author":"Vincent","year":"2003","unstructured":"Vincent A, McConville J, Farrugia ME, Bowen J, Plested P, Tang T, Evoli A, Matthews I, Sims G, Dalton P, Jacobson L, Polizzi A, Blaes F, Lang B, Beeson D, Willcox N, Newsom-Davis J, Hoch W (2003) Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci 998:324\u2013335","journal-title":"Ann N Y Acad Sci"},{"key":"1104_CR43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","volume":"247","author":"Walter","year":"2000","unstructured":"Walter MC, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M, Muller-Felber W, Pongratz D (2000) High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 247:22\u201328","journal-title":"J Neurol"},{"key":"1104_CR44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mus.10224","volume":"26","author":"Wolfe","year":"2002","unstructured":"Wolfe GI, Barohn RJ, Foster BM, Jackson CE, Kissel JT, Day JW, Thornton CA, Nations SP, Bryan WW, Amato AA, Freimer ML, Parry GJ (2002) Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 26:549\u2013552","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-005-1104-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-005-1104-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-005-1104-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T18:51:20Z","timestamp":1735757480000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-005-1104-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":44,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["1104"],"URL":"https:\/\/doi.org\/10.1007\/s00415-005-1104-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}